Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with neuroendocrine (NE) differentiation. Therapeutic strategies that address these aggressive variant PCs are urgently need...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Rep
Autors principals: Nyquist, Michael D., Corella, Alexandra, Coleman, Ilsa, De Sarkar, Navonil, Kaipainen, Arja, Ha, Gavin, Gulati, Roman, Ang, Lisa, Chatterjee, Payel, Lucas, Jared, Pritchard, Colin, Risbridger, Gail, Isaacs, John, Montgomery, Bruce, Morrissey, Colm, Corey, Eva, Nelson, Peter S.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7453577/
https://ncbi.nlm.nih.gov/pubmed/32460015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2020.107669
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars